Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rallybio Corp RLYB

Healthcare Biotechnology
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical... see more

Recent & Breaking News (NDAQ:RLYB)

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Business Wire 4 days ago

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Business Wire May 8, 2025

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Business Wire April 29, 2025

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Business Wire April 8, 2025

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Business Wire March 13, 2025

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Business Wire February 25, 2025

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Business Wire February 11, 2025

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Business Wire January 10, 2025

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Business Wire December 10, 2024

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Business Wire December 2, 2024

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Business Wire November 27, 2024

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Business Wire November 26, 2024

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Business Wire November 25, 2024

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Business Wire November 21, 2024

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Business Wire November 7, 2024

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Business Wire October 29, 2024

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Business Wire September 30, 2024

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Business Wire September 23, 2024

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Business Wire September 10, 2024

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Business Wire September 9, 2024